Oral therapy for Stargardt disease receives FDA fast track designation

The FDA granted fast track designation for an orally administered tablet for the treatment of Stargardt disease, according to a press release from Belite Bio.
The company expects near-term data on LBS-008, also known as Tinlarebant, from a phase 2 trial later this year. The therapy, which Belite said prevents the buildup of toxins in the eye that cause Stargardt disease and contribute to dry age-related macular degeneration, previously received rare pediatric disease designation in the United States and orphan drug designation in both the U.S. and Europe.
“At present, we are conducting a

The FDA granted fast track designation for an orally administered tablet for the treatment of Stargardt disease, according to a press release from Belite Bio.
The company expects near-term data on LBS-008, also known as Tinlarebant, from a phase 2 trial later this year. The therapy, which Belite said prevents the buildup of toxins in the eye that cause Stargardt disease and contribute to dry age-related macular degeneration, previously received rare pediatric disease designation in the United States and orphan drug designation in both the U.S. and Europe.
“At present, we are conducting a